Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition.

Henrik Junicke1, Jonathan R Hart, Jennifer Kisko

  • 1Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.

Proceedings of the National Academy of Sciences of the United States of America
|March 1, 2003
PubMed
Summary

A new rhodium(III) complex, rac-[Rh(bpy)(2)phzi](3+), acts as a DNA intercalator, efficiently cleaving mismatched DNA sites upon photoactivation. This targeted DNA cleavage shows promise for developing novel chemotherapeutics by distinguishing between cells with different DNA repair efficiencies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.

Blood advances·2026
Same author

The genetic basis of the immune response to SARS-CoV-2 infection and vaccination in the Italian municipality of Vo'.

Frontiers in immunology·2026
Same author

Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia.

Blood advances·2026
Same author

The constitutive oncogenic and signaling activities of phosphatidylinositol 3-kinase (PI3K) isoforms p110β and p110δ.

bioRxiv : the preprint server for biology·2025
Same author

Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor-Adoptive T-cell Therapy.

Blood cancer discovery·2024
Same author

Long Non-Coding RNAs as "MYC Facilitators".

Pathophysiology : the official journal of the International Society for Pathophysiology·2023

Area of Science:

  • Coordination Chemistry
  • DNA Intercalation
  • Photochemistry
  • Chemical Biology

Background:

  • DNA mismatch repair is crucial for genomic stability.
  • Targeting mismatched DNA sites offers therapeutic potential.
  • Rhodium(III) complexes can be designed as DNA-binding agents.

Purpose of the Study:

  • To design and synthesize a novel rhodium(III) complex, rac-[Rh(bpy)(2)phzi](3+), as a sterically demanding DNA intercalator.
  • To investigate the complex's ability to selectively bind and cleave mismatched DNA sites upon photoactivation.
  • To evaluate the complex's potential as a chemotherapeutic agent by assessing its differential activity in cells with varying mismatch repair proficiency.

Main Methods:

  • Synthesis of the rhodium(III) complex via condensation.

Related Experiment Videos

  • Characterization of DNA binding affinity using binding constants for various mismatches (e.g., CA, CC, CT) in oligonucleotide duplexes.
  • Assessment of site-specific photocleavage efficiency at nanomolar concentrations.
  • Differential DNA cleavage assays using DNA from cell lines proficient and deficient in mismatch repair.

    • Main Results:

    • The rhodium(III) complex rac-[Rh(bpy)(2)phzi](3+) was successfully synthesized.
    • The complex exhibits high affinity and efficiency in binding and cleaving single-base mismatched DNA sites.
    • Specific binding constants for CA, CC, and CT mismatches were determined (0.3, 1, and 6 x 10^7 M^-1, respectively).
    • Site-specific photocleavage occurred at nanomolar concentrations, maintaining specificity for mismatched over paired sites.
    • The complex demonstrated differential cleavage of DNA from mismatch repair-deficient versus proficient cell lines.

    Conclusions:

    • The designed rhodium(III) complex is a potent and selective agent for targeting and cleaving mismatched DNA.
    • The increased binding affinity is attributed to enhanced stacking interactions within the mismatched DNA site.
    • The complex's ability to differentiate between mismatch repair statuses suggests its potential as a novel chemotherapeutic strategy.